



(A Monthly, Peer Reviewed, Refereed, Scholarly Indexed, Open Access Journal)



Impact Factor: 8.524

Volume 14, Issue 1, January 2025





www.ijirset.com |A Monthly, Peer Reviewed & Refereed Journal| e-ISSN: 2319-8753| p-ISSN: 2347-6710|

Volume 14, Issue 1, January 2025 |DOI: 10.15680/IJIRSET.2025.1401043|

An In-Depth Review of Autism Spectrum Disorder and Recent Therapeutic Development

Miss. Shaik Yasmeen Sultana¹, Miss. G. Hima Bindu^{2*}, DR. K. Umasankar³, Dr. K. Venugopal⁴

Final Year B Pharmacy, Krishna Teja Pharmacy College, Tirupati, India¹

Assistant Professor, Department of Pharmaceutics, Krishna Teja Pharmacy College, Tirupati, India²

Professor and Head of the Department, Department of Pharmaceutics, Krishna Teja Pharmacy College,

Tirupati, India³

Professor and Principal, Krishna Teja Pharmacy College, Tirupati, India⁴

ABSTRACT: Autism Spectrum Disorder (ASD) is a complex neurodevelopmental condition characterized by persistent challenges in Social communication and restricted, repetitive behaviors. Manifesting in early childhood, ASD presents a diverse range of symptoms and severity uniquely impacting each individual. This review provides a comprehensive overview of ASD examining its genetic, perinatal and neurobiological foundations along with recent advancements in diagnostic methods. Additionally, the review discusses common comorbid conditions and treatment approaches including pharmacological, nutritional and assistive technologies. While substantial progress has been made in ASD management challenges remain particularly in achieving early diagnosis and addressing co-occurring conditions. This review underscores the ongoing need for personalized care strategies and a collaborative research approach to enhance the quality of life across the autism spectrum.

KEYWORDS: Autism Spectrum Disorder, Genetic and Perinatal Factors in ASD, Neuroimaging in ASD.

I. INTRODUCTION

Autism Spectrum Disorder (ASD) is a neurodevelopmental condition characterized by enduring challenges in social communication, alongside restricted, repetitive behaviors. These symptoms, which typically emerge in early childhood, can vary widely in severity, from mild to highly impairing. The term "spectrum" is used to capture the diversity of symptom presentations across individuals, as no two cases of ASD are exactly alike. Some individuals with ASD may exhibit intellectual disabilities and limited language skills, while others may demonstrate advanced language abilities and above-average intelligence, yet experience significant challenges in social communication. These difficulties often extend to the pragmatics of language such as speaking at an appropriate volume, recognizing personal space in social interactions, and interpreting gestures or facial expressions ^[4].

Historically, the understanding of ASD has developed significantly over the past century. The term "autistic" was first introduced by Swiss psychiatrist Eugen Bleuler in 1912 to describe the social detachment observed in schizophrenia. Later, Hans Asperger and Leo Kanner adapted this term to describe children with specific social and communication challenges.

By the time the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) was released, ASD became an umbrella diagnosis, merging previous distinctions of Autistic Disorder, Asperger's Syndrome, and Pervasive Developmental Disorder-Not Otherwise Specified (PDD-NOS) into a single spectrum. This reclassification acknowledges ASD as a continuum of related symptoms rather than distinct disorders.

ASD's complexity is shaped by developmental factors such as age and IQ as well as environmental influences, including access to interventions like individualized educational services, speech therapy and behavioral support. It is also commonly accompanied by co-occurring conditions, including intellectual disability, language disorder, and various medical or psychiatric conditions, such as epilepsy, sleep disturbances, anxiety, and depression ^[4].





www.ijirset.com |A Monthly, Peer Reviewed & Refereed Journal| e-ISSN: 2319-8753| p-ISSN: 2347-6710|

Volume 14, Issue 1, January 2025

|DOI: 10.15680/IJIRSET.2025.1401043|

Research suggests that ASD's causes are likely multifactorial, involving both genetic and environmental elements that impact early brain development. Observational studies reveal structural and functional brain variations among individuals with ASD, indicating atypical neural connectivity, especially in areas linked to socio-emotional processing [1,2,3].

II. UNDERSTANDING AUTISM SPECTRUM DISORDER

Autism Spectrum Disorder (ASD) is a neurodevelopmental condition, emerging in childhood that predominantly impacts behavior, language and communication in various ways. ASD presents across a broad range, with individuals at one end exhibiting average or near-average intelligence but facing challenges in communication and social interaction, often referred to as "high-functioning." On the opposite end are individuals with profound disabilities that significantly hinder daily functioning.

Though cases of individuals with "savant" abilities (Box 1) are often highlighted in media, they represent only a small fraction of the autistic population. Most individuals with autism face considerable impairments affecting independent living.

Autism was initially described by Kanner in 1943. Kanner identified two main traits among 11 children he observed: a distinct preference for solitude referred to as "autistic aloofness" and an intense need for consistency or "obsessive insistence on the preservation of sameness". He also noted their exceptional memory abilities, exemplified by one child, Donald, who demonstrated remarkable skills.

Thus, autism is primarily characterized by difficulties in connecting with others and engaging with the outside world. Affected individuals often have limited abilities in both verbal and nonverbal communication, accompanied by restricted, repetitive behaviors and fixated interests which may be seen in motor skills, language use and play behaviors [5]

Box 1: The Autistic Savant

The "autistic savant" is a captivating phenomenon in which an individual with autism possesses rare, extraordinary abilities that far surpass typical human capacities. These abilities, often in areas like music, math, visual arts, challenge scientific understanding even today. One well-known example is the character Raymond from *Rain Man*, inspired by Laurence K. Peek whose exceptional memory allowed him to retain vast amounts of information while still relying on his elderly father for daily living tasks. Other autistic savants like Derek Paravicini, can flawlessly replicate musical pieces after a single hearing or memorize entire phone books and calendar dates across years. Despite their outstanding skills these individuals often face profound challenges in other areas and need significant support for daily activities.

Although some autistic children display remarkable talents in certain fields true "autistic savants" are exceedingly rare. For most children with autism spectrum disorder, cognitive and social impairments. present significant challenges to typical functioning.

III. CAUSES OF ASD

Autism Spectrum Disorder (ASD) is a neurobiological condition influenced by genetic and perinatal factors affecting early brain development. Despite extensive research, no singular cause has been identified. Neuropathological studies have revealed structural and functional variations in brain regions such as the cerebellum, limbic system, and cortical areas ^[6]. Exploratory studies on neocortical architecture have demonstrated disruptions in cortical layer formation and neuronal differentiation. Brain overgrowth, including increased cortical size and extra-axial fluid, has also been documented in children with ASD, positioning these findings as potential biomarkers for further study ^[7].

3.1 Genetic Influences:

Genetic susceptibility plays a pivotal role in ASD. Siblings of individuals with ASD show a significantly increased risk of diagnosis, and monozygotic twins exhibit higher concordance rates compared to dizygotic twins. Advances in





www.ijirset.com |A Monthly, Peer Reviewed & Refereed Journal| e-ISSN: 2319-8753| p-ISSN: 2347-6710|

Volume 14, Issue 1, January 2025

|DOI: 10.15680/IJIRSET.2025.1401043|

genome-wide association studies and whole-exome sequencing have identified numerous ASD-related genes. These genes are commonly associated with brain development, neurotransmitter function and neuronal excitability ^[8]. Many implicated genes encode proteins involved in synaptic activity or neuronal responses including regulatory proteins such as transcription factors.

Epigenetic mechanisms, including DNA methylation and histone modifications, also contribute to ASD etiology ^[9]. Emerging research highlights novel genetic mechanisms such as those involving cytoskeletal structures and ion transport, broadening the understanding of ASD's molecular underpinnings. With over 700 associated genes, ASD is one of the most genetically heterogeneous neuropsychiatric disorders. However, phenotypic variability underscores the complexity of its genetic basis and its interplay with other influencing factors.

3.2 Perinatal Influences:

Perinatal factors may modulate genetic susceptibility to ASD. For instance prenatal exposure to substances like thalidomide and valproic acid has been associated with increased ASD risk ^[10]. Conversely, prenatal supplementation with folic acid, particularly in individuals exposed to antiepileptic drugs, has shown protective effects although broader recommendations require further evidence. Advanced maternal and paternal age have consistently been linked to increased ASD risk.

Maternal autoimmune conditions including diabetes and thyroid disorders and maternal infections during pregnancy have been investigated as potential risk factors though findings remain inconclusive. Additional factors such as shorter or longer inter-pregnancy intervals, premature birth, low birth weight and obstetric complications (e.g., uterine bleeding or cesarean delivery) have been associated with ASD. However, significant heterogeneity across studies limits definitive conclusions ^[11-12].

IV. DIAGNOSTIC METHODS FOR AUTISM SPECTRUM DISORDER

4.1 Traditional Diagnostic Approaches:

ASD diagnosis relies on comprehensive behavioral evaluations and developmental histories assessed by professionals such as pediatricians and neuropsychologists. This process involves structured interviews with caregivers and direct observation of social skills, communication and repetitive behaviors. The Autism Diagnostic Observation Scale (ADOS) assesses social interaction, communication and play, while the Autism Diagnostic Interview-Revised (ADI-R) gathers information on developmental history and behavior. Additionally, the Childhood Autism Rating Scale (CARS) evaluates behavioral patterns and severity. Physicians may also administer cognitive or developmental tests to differentiate ASD from other neurodevelopmental disorders. However, these methods may yield inconsistent results due to reliance on clinical judgment prompting the need for improved diagnostic techniques.

4.2 Latest Diagnostic Tools and Techniques:

Notably, recent advances have expanded the diagnostic toolkit beyond traditional approaches. Genetic testing has become increasingly important in identifying variations in specific genes associated with increased ASD risk. Variants in genes such as SHANK3, FMR1, MECP2 and NRXN1 are linked to syndromes often presenting ASD traits. Genetic insights provide families with a clearer understanding of ASD's underlying biology guiding tailored interventions and informing reproductive decisions.

4.3 Neuroimaging and Early Screening Methods:

Furthermore, neuroimaging techniques offer non-invasive insights into ASD's neural basis examining brain structure and function. Functional MRI (fMRI) observes activity patterns and neural connectivity while diffusion tensor imaging (DTI) examines white matter microstructure. Positron emission tomography (PET) measures neurotransmitter dynamics. These methods enhance understanding of ASD's neurological underpinnings potentially identifying biomarkers for improved diagnosis and treatment. Moreover, innovative early screening methods are revolutionizing ASD diagnosis. Artificial intelligence (AI) analyzes behavioral videos to detect ASD-linked patterns. Eye-tracking studies reveal distinctive gaze behaviors in ASD children. These tools, though in early development hold promise for wide-reaching early detection and personalized intervention ^[13].





www.ijirset.com |A Monthly, Peer Reviewed & Refereed Journal| e-ISSN: 2319-8753| p-ISSN: 2347-6710|

Volume 14, Issue 1, January 2025

|DOI: 10.15680/IJIRSET.2025.1401043|

V. PATHOLOGY OF AUTISM SPECTRUM DISORDER (ASD)

Research into ASD pathology has focused extensively on brain development and function identifying abnormalities at both the gross anatomical and cellular levels. Studies including experimental and postmortem analyses have highlighted neuropathological changes in neurons and glial cells underscoring the involvement of the central nervous system (CNS) in ASD. Recent investigations, however, reveal that pathologies extend beyond the CNS with emerging evidence pointing toward the immune system and gut-brain axis as potential contributors to ASD pathology ^[14].

5.1 Neuropathology:

Numerous studies have documented morphological abnormalities such as increased head circumference and intracranial volumes in young children diagnosed with ASD ^[15]. Meta-analyses have indicated alterations across brain regions, including the lateral occipital lobe, pericentral area, medial temporal lobe, basal ganglia and right parietal operculum. Nevertheless, large-scale data from sources like the Autism Brain Imaging Data Exchange (ABIDE) have been inconsistent, especially concerning findings in older individuals with ASD suggesting an early phase of abnormal brain overgrowth followed by developmental arrest or even degeneration. These discrepancies may stem from variations in methodologies participant sample sizes or age ranges highlighting the need for further research to refine our understanding. Despite these anatomical findings, a direct correlation between structural abnormalities and ASD clinical phenotypes remains elusive.

Brain connectivity studies in ASD reveal distinct patterns, with diminished distal region connectivity and increased proximal connectivity. However, this remains a subject of debate as several studies have failed to replicate these connectivity differences ^[16]. Furthermore, abnormalities in brain cytoarchitecture such as reduced cerebellar Purkinje cells have been noted. Yet the most consistent finding in ASD neuropathology is synaptic dysfunction. High-risk ASD-associated genes such as SHANK2/3, NRXN1 and NLGN4X encode synaptic proteins vital to brain function. Dysregulation of these genes influences pathways governing protein synthesis, chromatin remodeling and synaptic plasticity positioning ASD as a "synaptopathy" or a disorder primarily affecting synapse function. Two signaling pathways, mTOR/PI3K and NRXN-NLGN-SHANK are particularly implicated primarily affecting excitatory synapses and potentially leading to an imbalance in excitatory and inhibitory neural transmission.

5.2 Extra-cerebral Pathology:

Beyond the CNS alterations in other systems, particularly the gastrointestinal (GI) tract, have garnered significant attention. GI disturbances are highly prevalent among individuals with ASD with estimates ranging from 20% to 86%. Notably, the severity of GI issues often parallels ASD severity suggesting that GI function may influence ASD symptomatology. Common symptoms include abdominal pain, bloating, diarrhea, constipation and gastro-esophageal reflux.

In exploring the underlying mechanisms of GI disturbances in ASD the "leaky gut" hypothesis has emerged suggesting that increased intestinal permeability may contribute to systemic inflammation. This barrier dysfunction is similarly observed in GI disorders like Crohn's disease and celiac disease further linking GI health and ASD. Moreover, genetic forms of autism affecting the enteric nervous system highlight a direct CNS-GI connection leading to gut dysmotility. The gut-microbiome-brain axis has become a focal point in understanding ASD. Dysbiosis alterations in microbial diversity and composition have been observed in individuals with ASD with particular differences in Bacteroides and Firmicutes proportions. Though variability across studies exists due to methodological differences, geographic dietary factors and participant GI health statuses consistent findings suggest that microbial changes alongside impaired intestinal barriers may trigger inflammatory pathways impacting cerebral function thereby contributing to ASD neuropathology ^[17].

Together these CNS and extracerebral findings underscore the complex, multi-system nature of ASD pathology warranting further interdisciplinary research to deepen our understanding and explore potential therapeutic pathways ^[18].

VI. COMORBIDITY IN AUTISM SPECTRUM DISORDER (ASD):

The presence of two or more health conditions in one individual, known as comorbidity, plays a significant role in ASD diagnoses, as it helps in identifying which condition is primary and which is secondary ^[19]. ASD is often associated with





www.ijirset.com |A Monthly, Peer Reviewed & Refereed Journal| e-ISSN: 2319-8753| p-ISSN: 2347-6710|

Volume 14, Issue 1, January 2025

|DOI: 10.15680/IJIRSET.2025.1401043|

conditions like epilepsy, sleep disorders, gastrointestinal (GI) issues, toileting difficulties, behavioral challenges, ADHD, anxiety and depression. Studies indicate that roughly 70% of children and adolescents with ASD have atleast one additional disorder, with social anxiety frequently reported.

Overlapping symptoms from these comorbidities can obscure ASD characteristics, sometimes delaying diagnosis. For instance, a study found that 59% of children with ASD also had ADHD, which contributed to an average delay of four years in receiving an ASD diagnosis. Similarly, children initially diagnosed with ADHD were found to receive an ASD diagnosis an average of three years later than those without this additional diagnosis. This highlights the need for further research into how these overlapping conditions influence diagnosis timing. Early recognition of comorbidities allows healthcare providers to tailor treatments more precisely, aiming to balance efficacy with minimal side effects. Recognizing coexisting conditions also helps prevent "diagnostic overshadowing," where symptoms of one disorder are mistakenly attributed solely to ASD.

6.1 Gastrointestinal (GI) Symptoms:

Individuals with ASD are prone to GI issues at a rate higher than the general population, with estimates of prevalence ranging from 9% to 90%. GI complications such as abdominal pain, constipation and nausea are common and studies suggest that these issues are linked to other challenges like disrupted sleep, behavioral difficulties and social skill deficits. For example, discomfort from GI symptoms may lead to increased aggression or anxiety, impacting social interactions and behavior.

Research suggests specific GI symptoms can also correspond with psychological challenges. Nausea, for example, has been linked to behaviors associated with worry and withdrawal, while constipation and abdominal pain are associated with behavioral outbursts. However, more research is needed to clarify how GI symptoms intersect with the timing of ASD diagnosis and how age at diagnosis may influence symptom presentation.

6.2 Behavioral Challenges:

Defined as behaviors that significantly risk the individual's safety or limit social participation, "behavioral challenges" in ASD include aggression, self-injury and property destruction. In children, these behaviors may interfere with learning and social engagement and are often distressing for families. Behavioral issues may arise in response to physical discomfort or as a way of gaining attention.

Limited verbal skills among some individuals with ASD can hinder their ability to communicate discomfort, which may lead to misinterpretation by caregivers ^[20]. Recognizing ASD symptoms early can enable tailored interventions that reduce these behaviors, improving outcomes over time ^[21]. Currently, there is limited research on how these behavioral challenges may affect the age of ASD diagnosis, suggesting this as an area needing further study.



Fig 1: Comorbid Conditions in ASD. Reprinted from Leader et al. (2022), Age of Autism Spectrum Disorder Diagnosis and Comorbidity in Children and Adolescents with Autism Spectrum Disorder, Developmental Neurorehabilitation, 25(1), pp. 29-37. DOI: 10.1080/17518423.2021.1917717. Licensed under CC-BY-ND 4.0.

IJIRSET©2025





www.ijirset.com |A Monthly, Peer Reviewed & Refereed Journal| e-ISSN: 2319-8753| p-ISSN: 2347-6710|

Volume 14, Issue 1, January 2025

|DOI: 10.15680/IJIRSET.2025.1401043|

VII. TREATMENT FOR ASD

7.1 Drug Interventions:

Pharmacotherapy in Autism Spectrum Disorder (ASD) focuses on symptom management, particularly for behavioral issues that impact daily functioning. Antipsychotic drugs such as Risperidone are widely used due to their effectiveness in reducing irritability and aggression in children with ASD. Risperidone has shown greater efficacy than Haloperidol, although Haloperidol remains in use for managing acute agitation. Aripiprazole is another antipsychotic commonly prescribed for similar symptoms. While Clozapine despite its effectiveness is less favored because of significant side effects. To address anxiety which is common in ASD, Sertraline is frequently used as it has shown positive outcomes in reducing anxiety levels and improving adaptability.

Beyond antipsychotics, other drug classes are used based on specific symptoms. For example, Methylphenidate is effective for hyperactivity and impulsive behavior, while Venlafaxine helps reduce instances of self-injury. Selective serotonin reuptake inhibitors (SSRIs) like Fluoxetine and Citalopram are sometimes used to manage repetitive behaviors though their efficacy can vary by individual. Emerging treatments such as Cannabidiol (CBD) are being studied with early research indicating potential benefits in enhancing brain connectivity which could positively influence ASD symptoms associated with social interactions and cognitive flexibility. Although pharmacotherapy offers symptom relief, concerns about long-term side effects highlight the need for combining these interventions with behavioral therapies.

7.2 Nutritional Interventions:

Nutritional and dietary strategies are increasingly recognized as supportive treatments for individuals with ASD, as they can influence behavior and overall well-being. Gluten-free and ketogenic diets, for instance, have been associated with behavioral improvements though more research is needed to confirm the mechanisms behind these effects. Probiotic supplementation is another area gaining attraction studies suggest it may enhance gastrointestinal health which in turn can improve the quality of life for ASD patients who often experience gastrointestinal issues ^[22]. By supporting gut health, probiotics can help alleviate some physical discomfort that may otherwise exacerbate behavioral symptoms.

Vitamin supplementation is essential for managing deficiencies that are common in ASD. For example, Vitamin A may help in lowering elevated serotonin levels, while Vitamin C though not directly influencing ASD symptoms can prevent deficiency-related issues such as scurvy. B-complex vitamins play a role in reducing irritability, anxiety and sleep disturbances which are common in ASD. Vitamin D supplementation has shown potential benefits in improving social responsiveness and reducing symptoms related to emotional withdrawal. While these interventions are not replacements for primary treatments they provide valuable support especially when combined with other therapeutic approaches.

7.3 Assistive Technology Interventions:

Assistive technologies have made a significant impact on managing ASD, particularly in enhancing social, communication, and daily life skills. These technologies range from low-tech options, like visual schedules, to high-tech solutions such as communication apps, wearable devices, and therapeutic robots. Virtual environments are commonly used to develop social and collaborative skills, providing a safe space for ASD individuals to practice real-world interactions. Wearable devices, for instance, can track stress levels and provide biofeedback that helps individuals monitor and regulate their emotions effectively. However, despite their advantages, many technologies lack tactile engagement and accessibility, which limits their effectiveness for certain individuals [^{23-24]}.

Additionally, specialized communication apps and educational tools, like keyboards designed for sensory needs, support learning and interaction. While the development of these technologies has been rapid, there remains a gap in multi-user interfaces, which limits opportunities for collaborative play and interaction an area that could benefit from more focus. Overall, assistive technology complements other interventions, thereby promoting skills that are often challenging for ASD individuals to acquire through traditional means ^[25].

VIII. RESEARCH GAP

Although advancements have been made in Autism Spectrum Disorder (ASD) research still Key gaps remain in understanding the impact of Genetic, Molecular and Neurological variations on personalized treatment outcomes. The diversity in symptom presentation continue to challenge accurate diagnosis and the effectiveness of existing therapies.





www.ijirset.com |A Monthly, Peer Reviewed & Refereed Journal| e-ISSN: 2319-8753| p-ISSN: 2347-6710|

Volume 14, Issue 1, January 2025

|DOI: 10.15680/IJIRSET.2025.1401043|

There is a pressing need for future research to create precise diagnostic methods and tailored interventions that better address the unique needs of individuals with ASD thereby enhance their quality of life and support systems.

IX. CONCLUSION

Autism Spectrum Disorder (ASD) is a challenging condition that continues to demand attention and innovation. While strides have been made in understanding its underlying factors and developing new tools and treatments significantly gaps remain in areas such as early detection and managing co-occurring conditions. This review has emphasized the role of advanced diagnostics, therapeutic approaches and supportive technologies in improving the lives of those affected by ASD. However, given the wide-ranging nature of ASD symptoms a personalized and holistic approach is crucial. Moving forward dedicated research efforts should aim to address these challenges thereby fostering better care strategies and improving outcomes for individuals and their families.

REFERENCES

- 1. Park HR, Lee JM, Moon HE, et al. A short review on the current understanding of autism spectrum disorders. Exp Neurobiol. 2016 Feb;25(1):1-13. DOI:10.5607/en.2016.25.1.1.
- 2. Hirota T, King BH. Autism spectrum disorder: a review. JAMA. 2023;329(2):157-168. DOI:10.1001/jama.2022.2366.
- 3. Joon P, Kumar A, Parle M. What is autism? Maj Institute of Pharmacology Polish Academy of Sciences. 2021. DOI:10.1007/s43440-021-00244-0.10.
- Rydzewska E, Dunn K, Cooper SA. Umbrella systematic review of systematic reviews and meta-analyses on comorbid physical conditions in people with autism spectrum disorder. Br J Psychiatry. 2021; 218(1):10-19. DOI:10.1192/bjp.2020. 167.
- Zachariah SM, Oommen SP, Koshy B. Clinical features and diagnosis of autism spectrum disorder in children. Curr Med Issues. 2017;15:6-16.
- Johnson CP, Myers SM. Identification and evaluation of children with autism spectrum disorders. Pediatrics 2007; 120:1183-215. DOI: <u>10.1542/peds.2007-2361</u>.
- Hazlett HC, Gu H, Munsell BC, et al. Early brain development in infants at high risk for autism spectrum disorder. Nature 2017; 542:348-51.DOI: <u>10.1038/nature21369.</u>
- Walsh CA, Morrow EM, Rubenstein JLR. Autism and brain development. Cell 2008; 135:396-400. DOI: <u>10.1016/j.cell.2008.10.015</u>.
- 9. Voineagu I, Wang X, Johnston P, et al. Transcriptomic analysis of autistic brain reveals convergent molecular pathology. Nature 2011; 474:380-4. DOI: <u>10.1038/nature10110</u>.
- 10. Surén P, Roth C, Bresnahan M, et al. Association between maternal use of folic acid supplements and risk of autism spectrum disorders in children. JAMA 2013; 309:570-7. DOI: <u>10.1001/jama.2012.155925</u>.
- Wang C, Geng H, Liu W, et al. Prenatal, perinatal, and postnatal factors associated with autism: a meta-analysis. Medicine (Baltimore) 2017; 96:e6696. DOI: <u>10.1097/MD.00000000006696</u>.
- 12. Hodges H, Fealko C, Soares N. Autism spectrum disorder: definition, epidemiology, causes, and clinical evaluation. Transl Pediatr. 2020;9(Suppl 1):S55-S65. DOI:10.21037/tp.2019.09.09.
- 13. Qin L, Wang H, Ning W, et al. New advances in the diagnosis and treatment of autism spectrum disorders. Eur J Med Res. 2024;29:322. DOI:10.1186/s40001-024-01916-2.
- 14. Matelski L, Van de Water J. Risk factors in autism: Thinking outside the brain. J Autoimmun. 2016; 67:1–7. https://doi.org/10.1016/j.jaut.2015.11.003.
- 15. Haar S, Berman S, Behrmann M, Dinstein I. Anatomical Abnormalities in Autism? Cereb Cortex. 2016; 26(4):1440–52. <u>https://doi.org/10.1093/cercor/bhu242</u>.
- Mohammad-Rezazadeh I, Frohlich J, Loo SK, Jeste SS. Brain connectivity in autism spectrum disorder. Casanova MF, El-Baz A, Suri JS, editors. Curr Opin Neurol. 2016; 29(2):137–47. https://doi. org/10.1097/WCO.00000000000301.
- 17. Cryan JF, O'Riordan KJ, Cowan CSM, Sandhu K V, Bastiaanssen TFS, Boehme M, et al. The MicrobiotaGut-Brain Axis. Physiol Rev. 2019; 99(4):1877–2013. <u>https://doi.org/10.1152/physrev.00018.2018</u>.
- 18. Sauer AK, Stanton JE, Hans S, et al. Autism spectrum disorders: etiology and pathology. Exon Publications. 2021. DOI:10.36255/exonpublications.autismspectrumdisorders.2021.etiology.
- 19. Matson JL, Nebel-Schwalm MS. Comorbid psychopathology with autism spectrum disorder in children: an overview. Research in Developmental Disabilities. 2007; 28(4):341–52. DOI:10.1016/j. ridd.2005.12.004.





www.ijirset.com |A Monthly, Peer Reviewed & Refereed Journal| e-ISSN: 2319-8753| p-ISSN: 2347-6710|

Volume 14, Issue 1, January 2025

|DOI: 10.15680/IJIRSET.2025.1401043|

- Guastella AJ, Einfeld SL, Gray KM, et al. Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders. Biol Psychiatr. 2010; 67(7):692e694. DOI: <u>10.1016/j.biopsych.2009.09.020</u>.
- Leader G, Hogan A, Chen JL, et al. Age of autism spectrum disorder diagnosis and comorbidity in children and adolescents with autism spectrum disorder. Dev Neurorehabil. 2022;25(1):29-37. DOI:10.1080/17518423.2021.1917717.
- Arnold LE, Luna RA, Williams K, et al. Probiotics for gastrointestinal symptoms and quality of life in autism: a placebo-controlled pilot trial. J Child Adolesc Psychopharmacol. 2019; 29(9):659e669. doi: 10.1089/cap.2018.0156.
- 23. Canete R, Peralta E. Assistive technology to improve collaboration in children with ASD: state-of-the-art and future challenges in the smart products sector. *Sensors*. 2022; 22(21):8321. <u>https://doi.org/10.3390/s22218321.</u>
- 24. Aarabi MA, Abdi K, Khanjani MS. Using of rehabilitation services, the main concern of autism spectrum disorder: what can be done? *J Rehabil Sci Res*.2020; 7(4):189e190.
- 25. Kalra R, Gupta M, Sharma P. Recent advancement in interventions for autism spectrum disorder: a review. J Neurorestoratology. 2023;11:100068. DOI:10.1016/j.jnrt.2023.100068.









INTERNATIONAL JOURNAL OF INNOVATIVE RESEARCH

IN SCIENCE | ENGINEERING | TECHNOLOGY





www.ijirset.com